Sequencing-based tests to determine fetal down syndrome (trisomy 21) from maternal plasma DNA
BlueCross BlueShield Association
Record ID 32013000456
English
Authors' objectives:
The overall objective of this assessment is to determine whether nucleic acid sequencing-based testing for trisomy 21 using maternal serum improves outcomes of pregnancies screened for trisomy 21, compared to traditional serum and ultrasound testing strategies. Additionally, the evidence supporting similar objectives for trisomy 18 and 13 will be reviewed.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.bcbs.com/blueresources/tec/vols/27/27_10.pdf
URL for additional information:
http://www.bcbs.com/blueresources/tec/vols/27/sequencing-based-tests-to.html
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Prenatal Diagnosis
- Biomarkers
- Pregnancy
- High-Throughput Nucleotide Sequencing
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.